BS_ZV9Z3SY6
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 54.204993429697765
- age_years
- 16.866
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.481
- IL6_JAK_STAT3_SIGNALING+0.467
- ANGIOGENESIS+0.455
- TNFA_SIGNALING_VIA_NFKB+0.443
- INTERFERON_ALPHA_RESPONSE+0.438
- INTERFERON_GAMMA_RESPONSE+0.424
- COAGULATION+0.420
- ALLOGRAFT_REJECTION+0.417
- COMPLEMENT+0.416
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.401
Top 10 suppressed
- MYC_TARGETS_V1-0.644
- E2F_TARGETS-0.597
- MYC_TARGETS_V2-0.539
- G2M_CHECKPOINT-0.527
- OXIDATIVE_PHOSPHORYLATION-0.401
- DNA_REPAIR-0.321
- MTORC1_SIGNALING-0.317
- UNFOLDED_PROTEIN_RESPONSE-0.287
- MITOTIC_SPINDLE-0.267
- SPERMATOGENESIS-0.252
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797296 | — | cohortMD2 | 0.955 |
| 2 | BS_1RXZ3BP7 | low-grade glioma | — | 0.954 |
| 3 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.949 |
| 4 | SRR35579819 | — | A | 0.945 |
| 5 | SRR8518124 | — | D | 0.943 |
| 6 | SRR8392884 | — | cohortA1 | 0.939 |
| 7 | BS_FQX1PRAJ | Neurofibroma | — | 0.939 |
| 8 | MDT-AP-0384 | Med | Medulloblastoma | 0.935 |
| 9 | BS_69V8P8A0 | Neurofibroma | — | 0.935 |
| 10 | BS_401R3KV0 | pilocytic astrocytoma | — | 0.932 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.481 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.467 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.455 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.443 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.438 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.424 | Idelalisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.417 | Idelalisib | — uncovered |
| COMPLEMENT | 0.416 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.401 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.394 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.393 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.389 | Idelalisib | — uncovered |
| MYOGENESIS | 0.384 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.311 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APOPTOSIS | 0.299 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.295 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.285 | Inavolisib | — uncovered |